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Individuals with cerebral palsy (CP) report physical fatigue as a main cause of limitation, 
deterioration and eventually cessation of their walking ability. A consequence of higher level of 
fatigue in individuals with CP leads to a less efficient and long-distance walking ability. 
 
Research question 
This systematic review investigates the difference in 1) walking energy expenditure between 
individuals with CP and age-matched typically developing (TD) individuals; and 2) energetics of 
walking across Gross Motor Function Classification System (GMFCS) levels and age. 
 
Methods 
Five electronic databases (PubMed, Web of Science, CINAHL, ScienceDirect and Scopus) 
were searched using search terms related to CP and energetics of walking. 
 
Results 
Forty-one studies met inclusion criteria. Thirty-one studies compared energy expenditure 
between CP and age-matched controls. Twelve studies correlated energy expenditure and oxygen cost 
across GMFCS levels. Three studies investigated the walking efficiency across different ages or over 
a time period. A significant increase of energy expenditure and oxygen cost was found in individuals 
with CP compared to TD age-matched individuals, with a strong relationship across GMFCS levels. 
 
Significance 
Despite significant differences between individuals with CP compared to TD peers, variability 
in methods and testing protocols may play a confounding role. Analysis suggests oxygen cost being 



































































knowledge gap on age-related changes of walking efficiency across GMFCS levels and wider span 
of age ranges. Further systematic research looking at longitudinal age-related changes of energetics 
of walking in this population is warranted. 
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Cerebral Palsy (CP) is a non-progressive neurological disorder caused by a perinatal injury 
occurring in 2.0-3.5 per 1000 live births [1]. It is the most common cause of physical disability in 
children and primarily affects movement capacity. Individuals with CP have varying degrees of 
movement limitations depending on the type and level of severity and the affected brain area(s) [2]. 
Based on the Gross Motor Function Classification System (GMFCS), children with CP can be 
independently ambulatory (I, II), ambulatory with assistive devices (III), minimally ambulatory (IV) 
or predominantly use wheelchairs for mobility (V) [3]. Spastic CP is the most common subtype (~ 
80% of cases) [4], characterized by spasticity, muscle weakness and impaired selective motor control, 
all of which affecting the gait pattern and walking ability [5,6]. Muscles in children with CP also have 
a significant increase in extracellular matrix (ECM), measured via collagen content [7–9], 
histologically [10] and transcriptionally [11–13]. Reduced levels of daily physical activity in CP are 
associated with higher perceived fatigue [5]. Individuals with CP report physical fatigue as one of the 
main causes of limitation, deterioration and eventually cessation of their walking ability [5,14]. 
Studies involving functional tasks – such as walking and bimanual movements – showed increased 
selective muscle fatigue [15,16] and augmented external mechanical work [17]. Importantly, 
ambulatory children with CP, show reduced daily walking activity levels compared to typically 
developing (TD) children [18,19]. 
Walking capacity in individuals with CP often emerges as a multifaceted interplay of 
impairments at the neuromuscular, cardiorespiratory, and musculoskeletal systems [6,20,21]. Gross 
motor function in children with CP measured by the Gross Motor Function Measure (GMFM) [22,23] 
show changes in functional mobility over time, especially for the more severely impaired [24,25]. 
While GMFCS is normally stable for ambulatory children, those who are dependent on the use of 
assistive devices show a more pronounced loss of their ambulatory capacity [24,25]. Adults with CP 
have a reduction in walking capacity, with many studies reporting decline starting in their 20s and 



































































prevalence of secondary manifestations (e.g., pain, osteoporosis, and musculoskeletal problems) is 
higher in adults with CP compared to age-matched healthy adults [27–29]. Age-related changes in 
motor function and in gait proficiency is therefore an important clinical marker to monitor physical 
capabilities of the individual with CP over the years from childhood to adulthood. However, a broad 
assessment of the relationship between walking efficiency, functional levels, and the natural 
progression of ambulatory ability across the lifespan for individuals with CP is still poorly 
understood. 
Assessment of oxygen uptake (V̇O2) during submaximal exercise is a convenient and 
objective measure to determine walking efficiency in CP and evaluate changes after therapeutic 
interventions [30–33]. In addition, the measurement of energy expenditure while walking can provide 
a quantitative measure to evaluate differences between individuals with CP and age-matched TD 
individuals as well as to determine effective therapeutic interventions. Currently, a systematic 
approach primarily focused on studies that investigated energy expenditure by measuring V̇O2 during 
walking in population with spastic CP is lacking. Therefore, a comprehensive examination would 
further the understanding of the degree of impairment in walking energetics in individuals with 
spastic CP compared to age-matched TD individuals. Given the strong relationship between walking 
ability and GMFCS levels, it is also clinically relevant to summarize to what extent walking energy 
expenditure is related to GMFCS levels, and define the magnitude of change of energy expenditure 
across GMFCS levels. 
In summary, the aims of this systematic review were to identify, appraise and synthesize the 
evidence describing 1) the difference in energy expenditure in walking between individuals with CP 
and age-matched TD; 2) the relationship between V̇O2 and GMFCS levels; and 3) age-related changes 
in walking energy expenditure over time in individuals with CP. Findings will provide further insights 
into the extent of walking ability and its proficiency in individuals with spastic CP, and outline key 





































































This systematic review was completed following the Preferred Reporting Items for Systematic 
Review and Meta-Analyses (PRISMA) 2020 statement [34] (S1). The protocol was registered on 
Prospero (ID: CRD42020146657) [35], where a complete description of the methodology and the 
complete list of searched terms, the searching process, and data extraction method is available. 
 
Search strategy 
Relevant articles were identified by searching PubMed, Web of Science, CINAHL, 
ScienceDirect and Scopus databases using search terms related to the target population (cerebral 
palsy) and outcomes related to energetics (fatigue; energy metabolism; metabolic cost; energy cost; 
V̇O2; endurance; energy expenditure; aerobic capacity; oxygen consumption). The full electronic 
search strategy used for PubMed was as follows: ((((((((((((cerebral palsy[MeSH Terms]) OR 
(cerebral palsy[Title/Abstract])) AND (fatigue[MeSH Terms])) OR (fatigue[Title/Abstract])) OR 
(energy metabolism[MeSH Terms])) OR (energy metabolism[Title/Abstract])) OR (metabolic 
cost[Title/Abstract])) OR (energy cost[Title/Abstract])) OR (VO2[Title/Abstract])) OR 
(endurance[Title/Abstract])) OR (energy expenditure[Title/Abstract])) OR (aerobic 
capacity[Title/Abstract])) OR (oxygen consumption[Title/Abstract]). Search strategies for other 
databases is available in the supplementary material (S2). Two academic librarians were consulted to 
verify the codes used for the search terms. Studies published between January 1st, 1970 and November 
30th, 2019 were selected. Additional manuscripts were sought through cross referencing. 
 
Study selection 
Three authors (MN, FR, MB) independently searched through the databases and reviewed the 
titles and abstracts to remove articles that did not meet inclusion criteria. The following inclusion 
criteria were used: (1) walking tests (either over-ground or on the treadmill), (2) direct measures of 



































































and TD, CP across GMFCS levels or CP across different age groups. Exclusion criteria were: (1) 
animal models, (2) case and technical studies or reports, (3) interventional studies (i.e., drug, surgery, 
training and physical therapy) not reporting baseline measures, and (4) articles in other languages 
besides English. 
After preliminary screening, if the content from an abstract was unclear, article was included 
for a subsequent full manuscript review. The same three authors independently inspected the full 
texts, according to the inclusion/exclusion criteria. Any controversial article was discussed among 
the authors and resolved by consensus. Furthermore, reference lists of the included articles were 
reviewed to identify additional eligible papers that might have been missed during the first round of 
search. 
To assess study design, the American Academy of Cerebral Palsy and Developmental 
Medicine appraisal for categorization of evidence levels for group designs (Table I) [36] was used. 
Quality of study method was evaluated using a modified version of the American Academy of 
Cerebral Palsy and Developmental Medicine (AACPDM) guidelines in the protocol proposed by 
Morgan et al. [37], with only 12 out of 17 items for group studies (available as supplementary 
material: S3). Risk of Bias (RoB) was assessed using the Risk of Bias Assessment Tool for 
Nonrandomized Studies (RoBANS) [38]. In all cases, two authors (MN and FR) independently 
evaluated the studies, with any disagreements resolved by discussion and consensus. A third reviewer 
(MB) was consulted if necessary. 
 
Data extraction 
Two authors (MN and FR) extracted the pertinent data from the included articles using a 
customized data extraction form (S4). Study population characteristics (i.e., diagnosis, sample size, 
age, severity of CP) and details about the protocol used for the evaluation – such as the type of test 
(over-ground walking or on a treadmill); testing modality (self-paced, constant speed or incremental 



































































Table III. The primary outcomes were (1) energy expenditure and (2) energy cost (expressed in V̇O2, 
O2, kcal, MET or Joule), measured through indirect calorimetry or gas dilution methods. Articles 
reporting the same outcome were grouped for a coherent data categorization. Any reported secondary 
outcomes (i.e., HR, walking speed) were also collected. Findings were compared by difference 
between CP versus TD peers; difference between CP severity levels established by the GMFCS [3]; 
and differences across age groups or longitudinal changes. 
A meta-analysis to compare the differences between group means in CP and TD, for both 
energy consumption and energy cost, was conducted using a meta-analysis software (Review 
Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014). For the studies reporting alternative measure of descriptive statistics (e.g., 
median, IQ Ranges), Mean and SD or SE were estimated using formulae available in Cochrane’s 
Handbook [39]. Due to the heterogeneity in the primary outcomes among studies, and in some cases 
also the relatively small sample size (n<30), a random-effect model was fitted to the data for the 
calculation of the standardized effect size (Hedges’ d) [40,41] and 95% confidence interval (C.I.) 
[42]. An effect size of 0.2 to 0.49 was interpreted as a small effect, 0.5 to 0.79 a medium effect, and 
over 0.8 a large effect size [43]. Publication bias was assessed by visual inspection of funnel plots, 
then the Egger’s test was performed [44]. Heterogeneity was checked by means of the Higgins 
Inconsistency test (I2). Values over 50 % were considered of high heterogeneity [45]. 
For each study reporting values of energy consumption and/or energy cost across GMFCS 
levels I to III, linear correlation analysis using Pearson’s coefficient was run, with the level of 
impairment as the explanatory variable. Then, using the calculated correlation coefficients (r) and 
95% confidence interval (C.I.) of each study, the pooled correlation coefficient (r) and 95% C.I. were 
calculated using the Fisher r-to-z transformed correlation coefficient [46]. The heterogeneity of the 
pooled r was calculated using the Higgins Inconsistency test (I2) [45]. Values over 50 % were 



































































plots, then the Egger’s test was performed [44]. MedCalc for Windows, version 20.007 (MedCalc® 
Software Ltd, Ostend, Belgium) was used to perform the statistical analyses. 
 
Results 
Summary of studies 
After removing the duplicates, the initial search resulted in 1016 articles matching inclusion 
criteria. Eight hundred and nineteen articles were removed after title and abstract screening. The 
reasons for exclusion were: incorrect population (i.e., physical and mental disability other than CP), 
lack of metabolic data (e.g., biomechanics estimation or questionnaires score), and incorrect testing 
protocol (e.g., cycle-ergometer, isometric contractions). After the preliminary screening, 197 articles 
were kept for full-text review. Of these, 41 articles matched all the inclusion criteria [47–87]; reasons 
for exclusion of the additional 156 articles are listed in Figure 1. 
Regarding the methodological quality, the average score of the methodological quality 
appraisal was 52.6%. Twenty-three studies ranked medium-high quality (score > 58 %; 7/12 items) 
[48–52,56–58,63–70,73,74,76,79,82,83,86]. The main areas of methodological weakness found 
were: sensitivity of the measure to change (item 6), unawareness of outcome assessors during 
intervention (item 7); reporting the power calculation for the sample size (item 9), and reporting 
dropout/loss to follow-up (item 11). Individual scores of each article for methodological quality can 
be found as supplementary material (S3). 
All the included studies were screened with the RoBANS [38]. In most of the studies, CP and 
control groups were selected from comparable population group (80% of the studies). Concerning the 
confunding variables, these were adequately confirmed and considered during the design phase for 
59% of the studies, while it was uncertain whether the confounding variables resulted in a high risk 
or a low risk of bias for the remaining studies (41%). The experiemental protocols were described, 
and the outcomes used were valid and reliable in all the studies (100%). Low risk of bias for 



































































was reported for 98% and 88% of the studies, respectively. Complete summary of results for the ROB 
screening can be found in supplementary material (S5). 
A detailed summary of the characteristics and design of each study is provided in Table III, 
while details about protocol, energy expenditure outcomes, results and statistical significance for each 
study can be found in Table IV. 
Thirty-two articles compared metabolic data in people with CP and TD peers [47–56,58–
62,67–70,73–78,80,82,84–87]. Studies were grouped based on the outcome variable: twenty-one 
measured walking V̇O2 (ml/kg/min – either gross or net measure) [48,49,51,52,55–59,67–69,73–
77,82,84,85,87], one V̇O2max [61], two V̇O2peak [56,84], six adopted other measures of energy 
expenditure (i.e., kJ/min, kcal/min, J/kg/min) [47,50,54,70,75,80], twelve measured O2 cost of 
walking (ml/kg/m – either gross or net measure) [52,53,55–57,59,60,62,69,73,74,86], six calculated 
energy cost (J/kg/m) [49,51,54,58,68,87], and seven adopted other measures of energy cost of 
walking (i.e., non-dimensional cost, ml/kg-m) [49,51,54,58,74,77,82]. Seventeen studies reported 
more than one outcome and are therefore discussed for both outcomes [49,51,52,54–59,68,69,73–
75,82,84,87]. 
Twelve studies described the metabolic data across GMFCS levels [49,51,62–65,71,72,79,81–
83]; grouped based on outcome measures: seven walking V̇O2 (ml/kg/min – either gross or net 
measure) [49,51,63,79,81–83], seven O2 cost of walking (ml/kg/m – either gross or net measure) [62–
65,71,72,81], two energy cost (J/kg/m) [49,51], and five other measures of energy cost of walking 
[49,51,63,81,82]. Of these, five studies reported more than one outcome [49,51,63,81,82]. 
Only three studies compared metabolic data in people with CP [66,68,82], either across 
different age ranges [68] or longitudinally on the same individuals [66,82]. One of these studies 
reported the net O2 cost of walking (ml/kg/m) [66]; two articles reported multiple outcomes [68,82]: 
both measured walking V̇O2, one the energy cost (J/kg/m), and one other measures of energy cost of 



































































Five studies addressed multiple comparisons and thus were included in more than one 
subgroup: four research papers compared CP to TD and also CP across GMFCS levels [49,51,62,82]; 
one compared CP to TD and also addressed the effect of age in CP [68]; while one study performed 
all three comparisons of interest [82]. For this reason, the sum of studies in each subgroup differs 
from the total of forty-one articles. For a more comprehensive overview and comparison of the study 
results, and for graphical purposes, we converted – when possible – the originally reported values 
into V̇O2 (ml/kg/min) and O2 cost (ml/kg/m) using equations and formulae available from the 
literature (see details in [88]). Previously published V̇O2 and O2 cost values, and the converted or 
calculated ones, are shown in Figure 2 and 3, respectively. 
 
Testing protocols 
Protocol details and testing modalities were heterogeneous across studies (Table V). Few 
studies administered multiple tests with different outcomes, and are hereby included only for findings 
on energy expenditure and energy cost of walking. The most common testing modality was 
overground walking. Twenty-five studies tested subjects while walking on different tracks/paths of 
variable length and shape [49–54,57–60,62–66,69,70,73,74,79–83,86]; whereas twelve studies 
adopted a treadmill protocol [47,48,61,67,68,75–78,85,87]. One study used both testing modalities 
[56], while protocol description was unavailable for three studies [55,71,72]. Five studies 
administered an incremental walking test [61,68,76–78], thirty-two selected a constant speed walking 
protocol [47–52,54,57–60,62–67,69,70,73–75,79–87]. One study administered both an incremental 
and a constant-speed test [56]. In twenty-eight studies, subjects were asked to walk at comfortable, 
self-paced speed [47,49,51–54,56–60,62–66,69,70,73,74,79–83,86,87]. In nine studies, subjects were 
asked to walk at pre-determined speed and groups were compared at matched speed 
[47,48,56,67,68,75,83–85]. In three studies details were not provided [55,71,72]. Six-minute walking 
at self-paced speed [89] was the most common protocol, adopted by seven studies 



































































In patients with CP, the higher the level of mobility impairment (i.e., GMFCS level above II) 
the greater is the necessity of using assistive devices or orthoses for daily-life ambulation [3]. Nine 
studies did not report whether subjects were allowed to use their walking aids during test 
[59,68,71,72,75–78,83]. In twenty-two studies, subjects used their habitual walking aids and/or could 
hold on the handrail when the testing was on treadmill [47,49,51–56,60,62–67,69,70,74,79–82]. In 
ten studies, participants were not allowed to use or did not need walking aids for the test 
[48,50,57,58,61,73,84–87]. In nineteen studies subjects wore their habitual orthoses for the test 
[47,49,51–55,58,60,62–66,69,70,74,81,82], whereas in 4 studies subjects did not [57,61,73,87]. 
Eighteen studies did not provide information about the use of orthoses [48,50,56,59,67,68,71,72,75–
80,83–86]. 
 
Comparison of people with CP and typically developing peers 
Thirty-one out of 41 studies compared people with CP and TD. There were discrepancies 
across studies on group matching modality: some controlled for age, sex and body sizes, others only 
for age. In several studies the sample size was relatively small (n<30) [90], while in others the enrolled 
controls were fewer than the experimental CP group. 
 
Walking oxygen consumption (V̇O2) 
Oxygen consumption during walking (walking V̇O2) was the outcome for energy expenditure 
estimation in 19 studies [48,52,55–59,75,76,78,84,85,87]. Testing protocols used in these studies 
varied widely in terms of duration of resting (2 to 10 min) and walking time (3 to 10 min), setting 
(e.g., laboratory corridor, indoor and outdoor tracks) as well as testing modality (treadmill vs. 
overground walking) and walking speed (constant vs. incremental). 
One study measured V̇O2 (ml/kg/min) but then reported it in terms of energy units 
(Joule/kg/min) [54]; these values were re-converted for further comparison by the authors in the 



































































did not report an overall mean for CP, thus a weighted average was calculated using mean, standard 
deviation (SD) and sample size of the subgroups. Figure 2 shows the values reported in each of these 
studies. Original values (mean [Range]) TD: 14.28 [6.3–25.1] ml/kg/min; CP: 18.50 [9.72–26.86] 
ml/kg/min; recalculated values: TD: 17.94 [16.1–20] ml/kg/min; CP: 20.35 [17.06–22.46] 
ml/kg/min. Most of the studies reported a higher V̇O2 during walking for people with CP 
[48,49,51,54,55,58,59,69,74,75,78,82,84,87], however some studies described an opposite trend 
[57,73,76], and others revealed no appreciable difference between groups [47,56,87]. 
 
Walking oxygen cost (O2 cost) 
Fifteen studies measured values of walking O2 cost [52–60,62,69,73,74,86,87]. Four of these 
studies [54,58,86,87] reported it in J/kg/m; thus, these values were re-converted into ml/kg/min. We 
estimated O2 cost based on group means for 8 additional studies [48,49,51,61,75,76,82,84]. Three 
studies presented data for subgroups based on GMFCS levels [49,51,82] and 2 studies based on 
topographical distribution [53,59], without reporting an overall mean for CP. For this reason, a 
weighted average was calculated using mean, SD, and sample size of the subgroups. Figure 3 provides 
an overview of these 23 studies. Each study reported a higher O2 cost of walking for people with CP: 
Original values (mean [Range]) TD: 0.21 [0.05–0.28] ml/kg/m; CP: 0.49 [0.27–0.86] ml/kg/m; 
recalculated values: TD: 0.21 [0.12–0.36] ml/kg/m; CP: 0.34 [0.18–0.43] ml/kg/m, with a large 
heterogeneity in the magnitude of difference. 
 
Differences across CP severity levels (GMFCS) 
Twelve articles addressed comparison based on the level of severity (i.e., GMFCS levels) 




































































Walking oxygen consumption across severity levels  
Walking V̇O2 across severity was measured in seven studies [49,51,63,79,81–83]. One of 
these studies measured V̇O2 (ml/kg/min) but reported energy expenditure in METs [83]; thus, values 
were reconverted for analyses in the present review. Only three of these articles reported data for TD 
group [49,51,81]. Five out of seven studies reported a slight increment in V̇O2 increasing with 
GMFCS level with on average 15.1% (Range 3.8 – 44.0) increment between GMFCS I and II, and 
5.1% (Range -6.0 – 14.2) between GMFCS II and III. Values of walking V̇O2 across GMFCS levels 
are displayed in supplementary material (S6), with data of TD as a reference. 
Surprisingly, data in Thomas et al. [81] and Slaman et al. [79] showed an opposite trend for 
the GMFCS II - III comparison: V̇O2 in GMFCS III is lower than in GMFCS II, -2.4% and -6.0%, 
respectively. Results in Slaman et al. [79] also showed a steep V̇O2 increment between GMFCS I and 
II: +44.0%. 
 
Walking oxygen cost across severity levels 
Seven articles reported directly measured values O2 cost across the different severity stages 
[62–65,71,72,81]. We estimated values of O2 cost for the other five articles [49,51,79,82,83] using 
group mean data for V̇O2 walking speed or time, and distance travelled during evaluation test. Values 
of O2 cost across GMFCS levels are reported in Figure, with data of TD as a reference. In each study, 
O2 cost increased as a function of GMFCS level with a positive trend: on average 21.9% (Range 2.2 
– 55.6) increment between TD and GMFCS I, 37.8 % (Range 13.3 – 59.1) increment between 
GMFCS I and II, and 56.0% (Range 9.5 – 87.1) between GMFCS II and III. Only three studies 
[62,64,65] reported values of O2 cost for GMFCS IV and therefore are not shown in Figure 4; 
nevertheless, they confirmed the positive trend between O2 cost and severity level. Values are very 






































































Only three studies considered age as potential confounder of V̇O2 and/or O2 cost during 
walking [66,68,82]. Two longitudinal studies [66,82] assessed changes in the energy expenditure 
parameters over time in the same group of individuals with CP. The authors tested them at baseline 
and after 1 year [82] or 2 years and 7 months [66], respectively. Net O2 cost of walking was calculated 
by Kerr et al. [66], whereas walking V̇O2 was considered in the study by Thomas et al. [82]. The third 
study considering age was a cross-sectional design project testing subjects with CP at different speed 
on the treadmill while measuring V̇O2 and energy cost (EC; J/kg/m) [68]. Marconi et al. grouped 
subjects based on age ranges and clinical subtype (hemiplegia vs diplegia). Findings of these studies 
are contrasting. In the study by Kerr et al. [66] O2 cost deteriorated over time in individuals with CP, 
following a quadratic relationship with age (r=0.079; p=0.035). Thomas et al. [82] reported a 
significant decrease in walking V̇O2 over time only for TD peers, while there was no significant 
change in individuals across GMFCS levels of CP [82]. In the work of Marconi et al. [68] it was 
found that walking V̇O2 of individuals with diplegic CP was significantly higher than TD at each age, 
whereas in individuals with hemiplegic CP it was significantly higher only for the first age group (4-
7 years); however, they did not run statistical analysis to determine differences across age groups of 
the same CP subtype [68]. 
All three studies only evaluated young age ranges (years:months): 4:7–17:6 [66], 5:7–18 [82], 
and 4–14 [68], thus their results should be cautiously considered when generalizing the effect of age 
for older individuals. Because of the heterogeneity across studies in design, protocol, and outcome 






































































TD vs CP 
Comparison between TD and CP was feasible for both our main outcomes. Nineteen studies 
were included for the energy consumption analysis [48,49,51,52,54–58,69,73–76,78,82,84,85,87], 
while seventeen studies were included for the energy cost analysis [49,51–
58,60,62,69,73,74,80,86,87]. Effect size and C.I. were calculated for CP over TD group based on the 
random-effects model. Meta-analysis revealed a significant moderate to large effect of CP on both 
walking energy expenditure (Hedges’ g = 0.67 (95% CI: 0.34-0.99; Z = 4.03, p < 0.001; 
Heterogeneity: I2 = 76%; Figure 5) and energy cost of walking (Hedges’ g = 1.34 (95% CI: 1.21-
1.47; Z = 20.44 p < 0.001; Heterogeneity: I2 = 0%; Figure 6), respectively. Concerning the 
heterogeneity in the walking energy expenditure comparison, three studies presented a negative 
estimate for Hedges' g [57,73,76], with a higher walking V̇O2 for TD subjects compared to subjects 
with CP. Reasons for the contrasting results may be explained by the characteristics of the testing 
protocols. In the study by Piccinini et al. [73] and Cimolin et al. [57], participants walked for a short 
distance (250m), while in the study by Rose et al. [76], an incremental testing protocol was used and 
values at final step of the test are reported for both groups. Participants in TD group reached a higher 
maximal walking speed and V̇O2 at maximum speed (V̇O2peak) was higher than CP, in accordance 
with similar studies on cycle-ergometer [117,118] and treadmill [56,61,84]. It is worth to note that 
the results are consistent among studies when O2 cost, which takes into account walking speed, is 
considered (Figure 3 and Figure 6). The study by Rigby et al. [75] stands out for the considerable 
estimate of Hedges' g (>3). The sample size of the study was relatively small (8 TD, 8 CP) and the 
CP group was characterized by a medium-to-high severity involvement (4 spastic quadriplegia, 2 
spastic diplegia) [75] which may have exacerbated the between-group differences. Visual inspection 
of both funnel plots did not reveal asymmetry There was no evidence of publication bias for the 






































































Seven studies were included in the analysis for the V̇O2 [49,51,63,79,81–83]. The pooled r 
resulting from all the studies, based on the random-effects model was 0.965 (95% CI: 0.875-0.991; p 
< 0.001) and exhibited a notable heterogeneity (I2 = 98.07%). In particular, two studies [79,81] 
presented estimates much lower than the main bulk of results. In both studies, participants classified 
as GMFCS III had a lower V̇O2 during walking than participants classified as GMFCS II. This result 
could be explained by the reduced number of participants in the most impaired group (n=6) and the 
characteristics of the protocol (i.e., self-paced walking for 3 minutes) in the study by Slaman et al. 
[79]. In the study by Thomas et al. [81] the lower V̇O2 in GMFCS III could be ascribed to the 
functional limitations, and thus the much lower velocity reached by this group (difference between 
GMFCS II and III is appreciable when O2 cost is considered) [81]. Conversely, the study by Bolster 
et al. [51] resulted in an extremely high correlation coefficient. Nevertheless, sample size and 
participants distribution across groups appears appropriate and no obvious reason for considering it 
an outlier was apparent to the present authors. Twelve studies were included in the analysis for the 
O2 cost [49,51,62–65,71,72,79,81–83]. The pooled r resulting from all the studies, based on the 
random-effects model was 0.979 (95% CI: 0.966, 0.986; p < 0.001) and exhibited a notable 
heterogeneity (I2 = 94.19%). In particular, among the included studies, the one by Kerr et al. [65] 
stands out for the lowest correlation. As already mentioned, we only considered values of GMFCS I 
to III for the correlation analysis, while the study by Kerr et al. tested participants even with the level 
IV. Moreover, the difference in O2 cost between GMFCS I and II was minimal [65], lowering the 
correlation coefficient when considering only level I to III. In a similar, yet opposite manner, the 
extremely high correlation coefficient for the study by Johnston et al. [82] results from the exclusion 
of values for GMFCS IV – showing a marked increase in O2 cost and its variability – from our 
analysis. The study by Bolster et al. [51] also resulted in a high correlation. Nevertheless, sample size 



































































it an outlier was apparent to the present authors. Forest plots for both analyses are displayed as 
supplementary material (S7). Visual inspection of the funnel plot did not reveal asymmetry for the 
studies included for the V̇O2 correlation analysis. however, the number of studies included in the 
meta-analysis was too low to use tests for funnel plot asymmetry, as suggested in the Cochrane’s 
Handbook (<10 studies) [39]. Visual inspection of the funnel plot did not reveal asymmetry for the 
studies included for the O2 cost correlation analysis. Egger's test indicated that there was no obvious 
publication bias (p = 0.268). 
 
Discussion 
In the present systematic review, we aimed to 1) appraise and synthetize the difference in 
energy expenditure in individuals with CP compared to their age-matched peers; 2) identify the rate 
of V̇O2 across different severity levels, based on GMFCS; and 3) define the age-related changes of 
walking energy expenditure in individuals with CP. Forty-one studies met the inclusion criteria. 
Specifically, 31 studies compared V̇O2 during walking between individuals with CP and age-matched 
healthy subjects, 13 studies reported the changes of metabolic data across GMFCS and only 3 studies 
were found to investigate the variation of walking energy expenditure related to different ages. It is 
worth noting that several studies were considered for more than one aim of the current review. 
Overall, individuals with CP spend more energy (32% higher V̇O2 on average) than healthy 
controls while walking (average effect size equal to 0.67) [48,49,51,52,54–58,69,73–
76,78,82,84,85,87]. However, there were some conflicting results. For example, among the 20 
considered, 3 studies did not show any noticeable difference between CP and control group [47,56,87] 
and 3 studies found the opposite trend with healthy controls having higher walking V̇O2 [57,73,76]. 
The contrasting results may be related to the testing protocols. In the study by Piccinini et al. [73] and 
Cimolin et al. [57], participants walked for a short distance (~250m), equal to less than 4 minutes for 
TD and 5 minutes for CP group on average, respectively. In the study by Cardona García et al. [56], 



































































acceleration/deceleration phases in the walking cycle, which might represent a possible confounding 
effect and therefore a difference in the results obtained. Rose et al. [76] used an incremental testing 
protocol: values at final step of the test are reported for both groups. Participants in TD group reached 
a higher maximal walking speed and V̇O2 at maximum speed (V̇O2peak) was higher than CP, in 
accordance with similar studies on cycle-ergometer [117,118] and treadmill [56,61,84]. Finally, 
values of V̇O2 in Aviram et al. [47] were reported in kcal/min; this measure does not take into account 
for differences in body mass between groups, possibly masking the difference in walking energetics 
between groups. 
Conversely, when O2 cost – V̇O2 normalized by walking speed – was considered as the 
metabolic measure to evaluate walking efficiency, a remarkable difference was found between 
individuals with CP and healthy controls (average effect size equal to 1.34) [49,51–
58,60,62,69,73,74,80,86,87]. All studies reported significant higher values of O2 cost in CP during 
walking, as well as for those with estimated values by the authors. Thus, the distinguishable difference 
of O2 cost between groups was consistent with the testing type and protocol. On average, the O2 cost 
in individuals with CP was twofold than the age-matched controls with a range difference from 0.04 
to 0.62 ml/kg/m, which resulted with an increased O2 cost ranged from 1.3 to 3.5 times than controls. 
The remarkable greater cost of walking in CP respect to TD peers confirms the perceived 
effort and fatigue reported by children and adults with CP [5,91]. The O2 cost is considered a 
physiological marker describing the degree of locomotion impairment in pathological conditions such 
as multiple sclerosis [92], stroke [93], and Parkinson disease [94], and reflecting either an increase in 
the rate of V̇O2 during normal walking speed or an abnormal rate of V̇O2 respect to a reduced walking 
speed. It is worthwhile to consider that there is a U-shaped relationship between O2 cost and gait 
speeds, which indicates that there is a particular gait speed minimizing the O2 cost in each individual 
[95,96]. For this reason, when comparing CP to TD, the selection of walking speed needs to be 
carefully considered. A similar U-shaped relationship has been hypothesized in individuals with CP, 



































































[97,98] suggested an interesting way to compare data by means of a non-dimensional measure of 
energy expenditure, however the use of a non-dimensional outcome may not translate to clinical 
practice. Therefore, based on our results, we suggest O2 cost as the parameter to physiologically 
characterize the walking efficiency in people with CP. 
The ability to sustain a walking task for long period of time, maintaining an adequate force 
production with the lower possible O2 cost, is dependent on the integration of the neuromuscular and 
cardiorespiratory systems. Several factors play a role on one or more of these physiological systems 
that can lead to insurgence of fatigue and increase the energy cost of a functional task like ambulation. 
Among these factors specific have been recognized as the main ones affecting the duration of walking 
in CP. Neural-driven weakness, defined as a loss of excitatory motor signals descending in the 
cortico-spinal tract resulting in reduced muscle activation and reduced muscle size [99–101], seems 
to be a major limiting factor in this population. Rose and McGill [102] demonstrated an equivalent 
ratio between recruitment and firing rate modulation at submaximal contractions between subject 
with CP and controls. However, they showed that submaximal contractions required more voluntary 
effort for subjects with CP, such that the neuromuscular activation level corresponded about 50% of 
the maximum voluntary contraction (MVC) in individuals with CP compared to control whose 
neuromuscular activation level was related to about 20% of the MVC [102]. This means that a person 
with CP might require full voluntary effort compared to a submaximal effort for the healthy control. 
This reduced force-generating capacity of the muscle in individuals with CP might result with high 
relative demand of lower limb skeletal muscles during walking, making these individuals more prone 
to fatigue. These results are consistent with findings showing lower muscle endurance in quadriceps 
muscles of CP undergoing a submaximal repetition-to-fatigue protocol compared to control subjects 
[103]. In addition, it has been recently shown that the decrease of EMG median frequency and 
increase of EMG amplitude in lower leg muscles were larger in children with CP compared to 



































































Greater energy cost during walking in CP has been associated with higher external mechanical 
work [86,87], which has been associated with greater potential, vertical and later kinetic mechanical 
work [17]. The higher mechanical work was proposed to be related to the equinus gait pattern 
commonly seen in children with CP due to a less effective exchange between potential and kinetic 
energy by the legs to lift and redirect the center of mass [17,104–106]. Furthermore, it has been 
recently shown that reduced knee and hip joint extension are associated with gait inefficiency in 
children and adolescents with CP [107]. However, these results are in contrast with the work of Steele 
et al. [80] who found the crouch gait severity correlated poorly with elevated V̇O2 in in children with 
CP. Furthermore, it has also been recently reported that long-term reduction of spasticity by selective 
dorsal rhizotomy does not lead to reduced oxygen consumption [108]. 
Abnormal muscle activation patterns of agonist-antagonist, higher levels of co-contraction 
and impaired selective motor control are typical clinical signs of damaged corticospinal projections 
in CP [2,109,110], which have been shown to additionally contribute to gait abnormalities in this 
population [6]. It has been suggested that these impaired neural mechanisms of muscle activation 
might further contribute to the early manifestation of fatigue in CP [111]. Unnithan et al. [84] found 
that co-contraction of the quadriceps and hamstrings explained 51% of the variance in gross V̇O2 
among children with CP walking on a treadmill [84]. However, Damiano et al. [112] found the 
opposite relationship, with greater co-contraction between the quadriceps and hamstrings related to a 
lower energy expenditure index [112], and Steele et al. [80] showed that co-contraction of the rectus 
femoris and biceps femoris only explained 2–3% of the variance in V̇O2 during gait in children with 
bilateral CP. Moreover, despite the fact that the impaired selective motor control has showed a strong 
correlation with severity scales and gait abnormalities in CP [113–116], it is still uncertain whether 
decreased selective motor control is correlated with higher oxygen consumption during gait. 
Studies have reported lower maximal aerobic power in CP compared to controls without 
disabilities on treadmill and cycle ergometer tests [61,117]. Unnithan et al. [84] have shown that 



































































gait (53.5 % and 22.5 % respectively), which might explain an additional early onset of fatigue in 
individuals with CP since they work harder than the typically developing peers given speed. 
Interestingly, the respiratory exchange ratio has been found equivalent between individuals with CP 
and healthy controls, demonstrating similar cardiorespiratory responses in both group during 
submaximal exercise [76,117]. Though, it has been speculated that spastic muscles could cause local 
obstruction of venous return and, therefore, result in inhibition of muscle lactate clearance leading to 
increased acidity and local muscular fatigue [61,118]. However, no evidence has been provided to 
support this hypothesis, as well as it has yet been investigated the mechanism underlying skeletal 
muscle oxidative capacity in CP and its contribution to exercise intolerance and fatigue. 
Muscle metabolic factors might also reflect the increased O2 cost of movement in children 
with CP. Force generation is highly energetic and requires the constant replenishment of adenosine 
triphosphate (ATP) for the cross-bridge cycle, which is created aerobically within mitochondria by 
utilizing food substrates and oxygen consumption by the electron transport chain. Recent work shows 
that hamstring muscle mitochondria in even independently ambulatory children (GMFCS I and II) 
have a 50-80% lower capacity for energy production [119]. The metabolic machinery within the 
muscle also depends on the appropriate delivery of O2 to the mitochondria through appropriate 
development of the capillary network. In young adults with CP, reduced capillary density has been 
reported in wrist flexor contractures compared to control subjects [120], suggesting that it may have 
a role to play in reduced metabolic capacity. Exercise studies have shown that young adults with CP 
do get exhausted at lower exercise intensities, but they are able to dynamically increase muscle 
vascularization in response to exercise [121]. In general, more information is needed on how muscle 
metabolism is linked to the increased walking cost. 
We identified twelve studies that addressed the comparison between energy expenditure and 
GMFCS levels [49,51,62–65,71,72,79,81–83]. Overall, the results showed that the increased gross 
motor function severity was associated with an increased V̇O2 during walking. Yet, the considered 



































































level and the O2 expenditure compared to V̇O2. The increase of O2 cost was more accentuated between 
GMFCS II vs III (+56 %) compared to GMFCS I vs II (+38 %). Only three studies reported the O2 
cost for GMFCS IV, therefore they were not considered in the regression analysis with the other 
GMFCS levels. However, the results for these studies reported a trend of remarkable increased of O2 
cost in comparison of GMFCS III. Moreover, it is worth noting that the least difference (+22%) on 
cost was found between GMFCS I and TD age-matched controls considering both the originally 
measured and estimated values. This is not surprising since according to GMFCS individuals 
classified as level I can walk and run without any particular limitations that could impact their 
participation to daily activities [3]. 
As far as the age-related changes of walking energy expenditure in CP, we identified three 
studies that satisfied the search inclusion criteria [66,68,82]. However, only two studies analyzed and 
compared the cost of walking at different ages or over time [66,82]. Both studies reported an average 
increase of cost of walking in children with CP over a time period of 12 [82] or 31 months [66]. In 
comparison of the healthy control peers, Thomas et al. [82] found that all the GMFCS levels (I, II and 
III) had an increase in O2 cost over one year. Nevertheless, a lack of statistical difference was found 
in the magnitude of O2 cost increment by the GMFCS levels, which could had been influenced, as 
stated by the authors, by the short time period considered and the small sample size recruited for 
GMFCS levels I and II. The study by Kerr et al. [66] evaluated a large number of subjects with an 
age range (years:months) from 4:7 to 17:6. The relationship between the net O2 cost and age was 
found to have a turning point with the highest walking inefficiency at 12 years of age [66]. The authors 
argued that the energy inefficiency during walking at that age could be explained by the onset of the 
puberty and the changes of child’s education demands. The distinction across GMFCS levels was not 
accounted for in their analysis. It has been reported that gross motor function remains stable with age 
for children and adolescents classified as GMFCS level I [23]. Individuals that are more severely 
impaired (levels III and IV) see a decline in gait function with age [24,25]. Nonetheless, it remains 



































































levels. There is still a knowledge gap on the changes of O2 expenditure during walking in individuals 
at the early and late middle age with CP compared to age-matched unimpaired population. Further 
cross-sectional and longitudinal studies with larger sample size are needed to assess the trend of 
energy expenditure of walking with a broader range of ages classified at different GMFCS levels. 
Additionally, the wide range in energy expenditure and cost of walking values, and sometime 
inconsistent results, points out the need for more standardized protocols in clinical and experimental 
settings, as well as encouraging for large multicenter studies. This would provide a more 
comprehensive understanding of the progress of walking efficiency in individuals with CP at different 
severity levels from childhood to the adulthood. 
 
Conclusion 
The results of this review demonstrate a meaningful higher energy expenditure and energy 
cost during walking in individuals with CP despite a variability in the experimental protocols and 
testing type. A strong association between walking inefficiency and gross motor function was found 
across studies with a noticeable increase of cost of walking for GMFCS levels II and III. The analysis 
of the studies suggests a preference for using the O2 cost as a physiological parameter to assess 
walking efficiency in CP. Due to a limited number of studies, partially with small sample sizes, the 
impact of age-related changes on walking efficiency with different functional severity remains still 
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Figure 1: Article selection flowchart  
 
Figure 2: Values of walking V̇O2 in studies comparing data of CP to TD. Horizontal bars represent 
the mean for each group and error bars denote SD. Studies are listed in chronological order. Originally 
reported values are placed on the upper part, while the values estimated by the authors of the review 
are placed below. 
 
Figure 3: Values of walking O2 cost in studies comparing data of TD to CP. Horizontal bars represent 
the mean for each group and error bars denote SD. Studies are listed in chronological order. Originally 
reported values are placed on the upper part, while the values estimated by the authors of the review 
are placed below. 
 
Figure 4: Box plot showing values of O2 cost in TD and in CP across severity levels (GMFCS I to 
III). Triangles represent studies where values were converted or estimated by the authors of the 
review; dots indicate study originally measured data. Box plots depict the median and the 25th and 
75th quartiles and the whiskers showing the minimum and maximum values. Note, the highest point 
for TD (triangles) corresponds to the data in the study by Rose et al.,1989 [76], where they measured 
V̇O2 with participants walking at maximum speed. 
 
Figure 5: Forest plot with standardized effect sizes (Hedges' g) and C.I. for walking energy 
consumption in the comparison TD-CP. Positive values correspond to an effect of CP on the walking 





































































Figure 6: Forest plot with standardized effect sizes (Hedges' g) and C.I. for walking energy cost in 
the comparison TD-CP. Positive values correspond to an effect of CP on the energy cost. #Studies in 
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Table I. American Academy of Cerebral Palsy and Developmental Medicine appraisal for 
categorization of evidence levels for group designs. Level V studies (Expert opinion, Case 
studies/reports, Bench research) were excluded according to exclusion criteria. 
 
 
Level Intervention group studies 
I 
Systematic review of randomized controlled trials (RCTs) 
Large RCT (with narrow confidence intervals) (n >100) 
II 
Smaller RCT’s (with wider confidence intervals) (n<100) 
Systematic reviews of cohort studies 
“Outcomes research” (very large ecologic studies) 
III 
Cohort studies (must have concurrent control group) 
Systematic reviews of case control studies 
IV 
Case series 




Case study or report 
Bench research 
Expert opinion based on theory or physiologic research 
Common sense/anecdotes 
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Table II. Summary of characteristics of the included studies. 
 
Study 




Population and sample size (subgroups) Age (years:months; mean + SD) Testing type 
Aviram et al., 2011 [47] Cross sectional study - III I-III 28 children (7 TD, 21 CP: 8 GMFCS I, 6 GMFCS II, 7 GMFCS III) 
TD = 7:3 ± 1:0 
CP = 6:5 ± 1:11 
treadmill walking 
Balaban et al., 2012 [48] Interventional study - II/III N/A 29 children (13 TD, 16 spastic CP) 
TD = 11:5 ± 2:10 
CP = 11:1 ± 1:8 
treadmill test (submaximal) 
Balemans et al., 2017 [49] 
Cross sectional study - 
II/III 
I-III 
57 children and adolescents (20 TD, 37 spastic CP: 13 GMFCS I, 
17 GMFCS II, 7 GMFCS III) 
TD = 11:10 ± 3:6 
GMFCS I = 11:5 ± 3:1 
GMFCS II = 13:1 ± 3:8 
GMFCS III = 16:5 ± 4:1 
self-paced walking 
Bell and Davies 2010 [50] Cross sectional study - III I-II 32 children (16 TD, 16 spastic CP: 8 GMFCS I, 8 GMFCS II) 
TD = 8:7 ± 2:7 
CP = 8:11 ± 2:2 
self-paced walking 
Bolster et al., 2017 [51] Cross sectional study - II I-III 
191* Children and young adults (63 TD, 128 CP: 48 GMFCS I, 56 
GMFCS II, 24 GMFCS III) 
*value at rest for 180 (net and NN EC) 
TD = 12:5 ± 4:11 
GMFCS I = 10:8 ± 3:9 
GMFCS II = 12:8 ± 4:3 
GMFCS III = 11:6 ± 4:3 
self-paced walking 
Bowen et al., 1998 [52] Cross sectional study - III N/A 10 children (5 TD, 5 CP) 
TD = 9:6 ± 3:1 
CP = 10:0 ± 4:5 
self-paced walking 
Boyd et al., 1999 [53] 
 
Cross sectional study - 
II/III 
N/A 
182 children with motor disabilities (5 TD, 133 CP [4 Hemiplegia, 
10 Quadriplegia, 119 Diplegia], 26 Spina bifida, 18 Femoral shaft 
fractures) 
N/A self-paced walking 
Brehm et al., 2007 [54] 
(preliminary) Repeated 
measure - III 
I-III 
23 children (10 TD, 13 spastic CP) 
*6 TD, 9 CP (resting and net values) 
TD = 8:11 ± 3:3 
CP = 8:7 ± 3:4 
self-paced walking 
Campbell and Ball 1978 [55] Cross sectional study - III N/Aa TD children (n not reported) and 22 spastic diplegic CP 
TD = 10:0 ± 2:1 
CP = 10:6 ± 2:9 
N/A 
Cardona Garcia et al., 2016 [56] Cross sectional study - II I-II 80 children (40 TD, 40 CP) 
TD: 11 ± 3:7 
CP: 11 ± 3:4 
1) self-paced walking 
2) Incremental treadmill walking 
test 
Cimolin et al., 2007 [57] Cross sectional study - II N/A 40 children (20 TD, 20 spastic hemi/diplegic CP) 
TD = 7:9 ± 2:1 
CP = 8:8 ± 2:7 
self-paced barefoot walking 
Dallmeijer and Brehm 2011 [58] Cross sectional study - III I-II 18 children (10 TD, 8 mild spastic CP) 
TD = 9:10 ± 2:11 
CP = 9:11 ± 3:0 
self-paced walking 
Duffy et al., 1996 [59] Cross sectional study - III N/Aa 
56 children (16 TD; CP: 13 Diplegia, 6 Hemiplegia; Spina bifida: 
11 L3/4, 10 L5/S1) 
TD = 9 (5-12) 
Diplegia = 8:6 (4-12) 
Hemiplegia = 5:6 (5-7) 
(Range) 
self-paced walking 
Gupta and Raja 2019 [60] Longitudinal study - III I-III 
138 children (58 TD, 80 spastic diplegic CP: 6 GMFCS I, 11 
GMFCS II, 63 GMFCS III) 
Overall range: 6-18 
(mean and SD not reported) 
self-paced (outdoor) walking 
Hoofwijk et al., 1995 [61] Cross-sectional study - III N/Aa 18 children (9 TD; 9 CP) 
TD = 14:0 ± 2:5 
CP = 13:6 ± 2:8 
maximal incremental treadmill 
walking test 
Johnston et al., 2004 [62] Cross sectional study - III I-IV 
57 children (30 TD, 27 CP: 5 GMFCS I, 10 GMFCS II, 9 GMFCS III, 
6 GMFCS IV) 
TD = 10:0 ± 1:6 
CP = 9:6 ± 2:4 
self-paced walking 
Kamp et al., 2014 [63] 
(retrospective) Cross-
sectional study - II 
I-III 
276 children with spastic CP (79 GMFCS I, 123 GMFCS II, 74 
GMFCS III 
GMFCS I: 12:10 (4:11) 
GMFCS II: 12:6 (4:11) 
GMFCS III: 11:3 (4:8) 
*Median (Interquartile range) 
self-paced walking 
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Study 




Population and sample size (subgroups) Age (years:months; mean + SD) Testing type 
Kerr et al., 2007 [64] Cross sectional study - II I-IV 
47 children with bilateral spastic CP (6 GMFCS I, 27 GMFCS II, 10 
GMFCS III, 3 GMFCS IV) 
CP (overall): 11:8 ± 3:6 
GMFCS I: 11:11 ± 3:3 
GMFCS II: 10:9 ± 3:6 
GMFCS III: 13:5 ± 3:5 
GMFCS IV: 13:5 ± 2:1 
self-paced walking 
Kerr et al., 2008 [65] Cross-sectional study - II I-IV 
115/184 ambulant children with CP 
(64/94 unilateral-, 47/84 bilateral-spastic, 4/6 non-spastic) 
(44/57 GMFCS I, 55/91 GMFCS II, 11/22 GMFCS III, 5/14 GMFCS 
IV) 
*O2 cost assessment 
CP (overall): 10:9 ± 3:7 
GMFCS I: 12:1 ± 0:5 
GMFCS II: 9:11 ± 0:4 
GMFCS III: 10:11 ± 0:11 
GMFCS IV: 11.9 ± 0:11 
self-paced walking 
Kerr et al., 2011 [66] Longitudinal study - II I-IV 
ambulant children with CP 
baseline: 184* (57 GMFCS I, 91 GMFCS II, 22 GMFCS III, 14 
GMFCS IV) 
2nd visit: 157* (55 GMFCS I, 70 GMFCS II, 16 GMFCS III, 10 
GMFCS IV, 6 Missing) 
*85 matched net O2 cost data 
CP (visit 1) = 10:10 ± 3:7 
CP (visit 2) = 13:4 ± 3:6 
self-paced walking 
Maltais et al., 2004 [67] Cross sectional study - III I-II 
20 children and adolescents (10 TD, 10 mild spastic hemi/diplegic 
CP) 
TD = 13:0 (10:7-16:7) 
CP = 13:0 (10:4-16:4) 
(Range) 
submaximal treadmill walking in 
the heat 
Marconi et al., 2012 [68] 
Cross sectional study - 
II/III 
N/A 63 children (20 TD, 43 CP: 11 Hemiplegia, 32 Diplegia) 
TD = 9:4 ± 2:6 
CP (Hemiplegia)= 8:6 ± 4 
CP (Diplegia) = 7:6 ± 7:6 
incremental treadmill walking test 
Norman et al., 2004 [69] Cross sectional study - III N/A 25 children (15 TD, 10 spastic diplegic CP) 
TD = 11:8 ± 2:8 
CP = 12:10 ± 2:11 
self-paced walking 
Norman et al., 2006 [70] Cross sectional study - III N/A 15 children (10 TD, 5 spastic diplegic CP) 
TD = 12:7 ± 2:10 
CP = 13:8 ± 3:7 
self-paced walking 
Oeffinger et al., 2004 [71] 
(retrospective) Cross 
sectional study - II 
I-III 
1047 [419] ambulatory children with CP (GMFCS I: 457 [179]; 
GMFCS II: 286 [134]; GMFCS III: 304 [106]) 
*in brackets [ ]: subjects with O2 cost assessment 
CP (overall) = 11:2 ± 4 
GMFCS I = 10:9 ± 4 
GMFCS II = 11:2 ± 4:3 
GMFCS III = 10:7 ± 4:2 
*all participants (not everyone with O2 cost) 
walking test 
Oeffinger et al., 2007 [72] Cross sectional study - II I-III 
562 children with hemi/diplegic CP (180/240 GMFCS I, 140/196 
GMFCS II, 65/126 GMFCS IIII) 
*O2 cost assessment 
CP (overall) = 11:1 ± 3:8 
GMFCS I = 11:4 ± 3:8 
GMFCS II = 11:0 ± 3:8 
GMFCS III = 12:7 ± 3:4 
N/A 
Piccinini et al., 2007 [73] Cross sectional study - II N/A 40 children (20 TD, 20 spastic hemi/diplegic CP) 
TD = 7:9 ± 2:1 
CP = 8:8 ± 2:7 
self-paced barefoot walking test 
Plasschaert et al., 2008 [74] 
Cross sectional study 
(repeated measures) - II 
N/A 84 children (42 TD, 42 CP) 
TD = 11:5 ± 2:1 
CP = 12:0 ± 2:7 
self-paced walking tests (2 
conditions: normal, +10% BW) 
Rigby et al., 2017 [75] Interventional study - II/III N/A 16 children (8 TD, 8 spastic CP) 
TD = 10:7 ± 2:1 
CP = 10:4 ± 4:5 
treadmill test (submaximal) 
Rose et al., 1989 [76] Cross sectional study - III N/Aa 31 children (18 TD, 13 spastic CP: 4 Hemiplegia, 9 Diplegia) 
TD = 12:6 (7-17) 
CP = 11:2 (7-16) 
(Range) 
incremental treadmill walking test 
Rose et al., 1990 [77] Cross sectional study - III N/Aa 31 children (18 TD, 13 spastic CP: 3 Hemiplegia, 10 Diplegia) 
TD = 12:6 (7-17) 
CP = 11:2 (7-16) 
(Range) 
incremental treadmill walking test 
Rose et al., 1993 [78] Cross sectional study - III N/Aa 31 children (18 TD, 12 spastic CP: 3 Hemiplegia, 9 Diplegia) 
TD = 12:7 ± 3:8 
CP = 11:6 ± 2:5 
incremental treadmill walking test 
Study 




Population and sample size (subgroups) Age (years:months; mean + SD) Testing type 
Slaman et al., 2013 [79] Cross-sectional study - III I-III 
36 adults with spastic bilateral CP (9 GMFCS I, 21 GMFCS II, 6 
GMFCS III) 
CP (overall) =36 ± 6 
*not reported for subgroups 
self-paced walking 
Steele et al., 2017 [80] 
(retrospective) Cross-
sectional study - II 
N/A 
650 children (77 TD*, 573 bilateral CP) 
*data from a TD database 
TD = 10:8 ± 4:2 
CP = 10:4 ± 3:11 
self-paced walking 
Thomas et al., 2009 [81] Cross sectional study - III I-III 
23 children with spastic diplegic CP (10 GMFCS I, 8 GMFCS II, 5 
GMFCS III) 
CP (overall) = 11:2 ± 0:2 
GMFCS I =11:6 ± 0:2 
GMFCS II = 11:0 ± 0:4 
GMFCS III = 11:0 ± 0:5 
self-paced walking 
Thomas et al., 2011 [82] 
Longitudinal cohort study 
- III 
I-III 
79 children (45 TD; 34 spastic diplegic CP: 16 GMFCS I, 13 
GMFCS II, 5 GMFCS III) 
TD = 11:1 ± 3:5 
GMFCS I = 12:8 ± 3:0 
GMFCS II = 12:4 ± 3:6 
GMFCS III = 11:0 ± 4:9 
self-paced walking 
Trost et al., 2016 [83] 
Cross sectional study - 
II/III 
I-III 51 youth with CP (27 GMFCS I, 12 GMFCS II, 12 GMFCS III) 
GMFCS I = 12:5 ± 3:4 
GMFCS II = 12:4 ± 3:5 
GMFCS III = 12:8 ± 3:1 
3 walking trials: comfortable-, 
brisk- and fast-speed 
Unnithan et al., 1996 [84] Cross sectional study - III N/Aa 
18 children (8 TD*; 9 spastic CP: 7 diplegic, 1 hemiplegic, 1 
quadriplegic) 
*8/9 TD considered 
TD = 13:7 ± 2:1 
CP = 12:8 ± 2:10 
maximal and submaximal treadmill 
walking test 
Unnithan et al., 1999 [85] Cross sectional study - III N/A 
13 children (5 TD, 8 spastic CP: 6 diplegic, 1 hemiplegic, 1 
quadriplegic) 
TD = 13:5 ± 2:10 
CP = 12:2 ± 2:8 
submaximal treadmill walking test 
Van de Walle et al., 2012 [86] Cross-sectional study - III I-II 
48 children (18 TD children, 11 TD adults, 19* children with spastic 
diplegic CP) 
*11 O2 cost measures available 
TD children = 9:4 [7:8–10:7]* 
TD adults = 24:8 [23:6–28:6]* 
CP children = 10:1 [9:10 -10:10]* 
*Median and inter quartile ranges [IQ1–IQ3] 
self-paced walking 
Van Den Hecke et al., 2007 [87] 
Cross sectional study - 
II/III 
N/A 26 children (6 TD, 20 spastic hemiplegic CP) 
TD = 9:11 ± 0:7 
CP = 8:1 ± 1:7 
treadmill walking (at comfortable 
overground speed) 
CP, cerebral palsy; TD typically developing; GMFCS, Gross Motor Function Classification System (level); CWS, comfortable walking speed; FWS, fastest walking speed; N/A, not available; avg, average; aarticle published before 
1997 (year of GMFCS development); s-s, at steady-state. Age is reported in years:months for all the included studies (converted when originally reported in years only). 
 
Table III. Summary of protocol, outcome measures, main results and statistics for the included studies. 
 
Study Protocol Energy expenditure outcome (s) Main results SS 
Aviram et al., 2011 [47] 
1) self-paced walking (4 min); 
2) treadmill walking at CWS +20-30% 
EE rate (Kcal/min) 
CWS: 
TD: 2.10 ± 0.28 
CP: 1.71 ± 0.79 
CWS +20-30%: 
TD: 2.07 ± 0.36 
CP: 2.43 ± 1.14 
N/A N/A 
Balaban et al., 2012 [48] 5 min treadmill constant speed (0.5 m/s) walking. 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 7.83 ± 0.83 
CP (baseline): 9.72 ± 1.51 
Higher ?̇?𝑂2 in CP group at baseline. P=0.001 
Balemans et al., 2017 [49] 6 min walking on an oval track. 
(gross) Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 20.0 ± 5.8 
GMFCS I: 21.2 ± 4.0 
GMFCS II: 22.0 ± 5.6 
GMFCS III: 24.0 ± 4.4 
EC (J/kg/min): 
TD: 4.9 ± 1.1 
GMFCS I: 6.0 ± 1.2 
GMFCS II: 7.2 ± 1.5 
GMFCS III: 10.6 ± 2.9 
 
Higher EC in CP, increasing with severity. 
P<0.001 (each 
comparison) 
Bell and Davies 2010 [50] 
5 min rest (sitting); 
10 min walking (oval 20m track); 
5 min rest (sitting). 
Walking EE (kJ/min): 
TD: 10.3 ± 2.3 
CP: 13.8 ± 4.9 
* adjusted for body size (power function models) 
Higher walking EE in CP P<0.05 
Bolster et al., 2017 [51] 
5 min rest; 
6 min walking on an indoor oval track (40 m). 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 18.46 (0.58) 
GMFCS I: 20.81 (0.67) 
GMFCS II: 22.75 (0.62) 
GMFCS III: 25.09 (0.95) 
Gross [net] EC (J/kg/m): 
TD: 4.93 (0.19) [3.11 (0.16)] 
GMFCS I: 5.90 (0.22) [4.00 (0.20)] 
GMFCS II: 7.69 (0.20) [5.45 (0.17)] 
GMFCS III: 10.89 (0.31) [7.68 (0.27)] 
*Mean (SE) 
 
Higher walking ?̇?𝑂2, gross EC, net EC in CP subgroups. 
All EC measures differ significantly between GMFCS 
levels, walking ?̇?𝑂2 only between level I and III. 
P<0.001 
Bowen et al., 1998 [52] 
2 min rest (supported sitting); 
walking on an indoor oval track for a recorded 
distance (219-598 m); 
2 min rest (supported sitting). 
*5 measurements within 65 days 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 19.78 ± 4.51 
CP: 26.86 ± 2.58 
O2 cost* (ml/kg/m)   *?̇?𝑶𝟐/distance walked: 
TD: 0.27 ± 0.06 
CP: 0.42 ± 0.07 
Higher O2 cost and ?̇?𝑂2 in CP group. P<0.001 
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Study Protocol Energy expenditure outcome (s) Main results SS 
Boyd et al., 1999 [53] 
 
5 min rest; 
10 min walking (10m oval track). 
(gross) O2 cost (ml/kg/m): 
TD group: 0.28 ± 0.06 
Hemiplegic CP: 0.36 ± 0.17 
Quadriplegic CP: 0.51 ± 0.23 
Diplegic CP (total): 0.54 ± 0.27 
Higher O2 cost in the most impaired 
(hemiplegia<quadriplegia and diplegia). 
N/A 
Brehm et al., 2007 [54] 
10 min rest (sitting, watching a video); 
5 min walking (50-m indoor oval track). 
*Repeated 4 times in 4 weeks 
Gross (net) ECS (J/kg/min) 
TD: 359 (224) ± 55 (35) 
CP: 433 (275) ± 101 (67) 
Gross (net) EC (J/kg/m): 
TD: 4.80 (2.90) ± 0.8 (0.3) 
CP: 6.84 (4.40) ± 2.0 (1.5) 
*missing values at rest for 8 subjects (4 CP, 4 TD) 
Higher gross- and net energy consumption (ECS), energy 
cost (EC) in CP; higher ECS at rest in CP. 
P<0.001, P<0.013 (ECS 
at rest) 
Campbell and Ball 1978 [55] N/A 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 18.1 ± 3.30 
CP: 22.9 ± 6.17 
O2 cost (ml/kg/m): 
TD: 0.247 ± 0.045 
CP: 0.862 ± 0.851 
Higher ?̇?𝑂2 and O2 cost in CP group P<0.0005 
Cardona Garcia et al., 2016 [56] 
1) Walking test: 
6-min walk (over 5 m) 
2) Incremental treadmill walking*: 
 Initial speed: 2.0 km/h + 0.1 km/hr and 0.5% 
grade every 15 sec until exhaustion 
*not clear if allowed to run 
 ?̇?𝑶𝟐 walk (ml/kg/min): 
CP: 12.2 ± 3.7 
TD: 12.1 ± 2.8 
O2 cost (ml/kg/m): 
CP: 0.265 ± 0.09 
TD: 0.167 ± 0.05 
Higher O2 cost in CP P<0.001 
Cimolin et al., 2007 [57] 
2 min rest (sitting); 
7 laps (250m in total) of walking; 
2 min recovery (sitting) 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 15.6 ± 3.21  
CP: 13.97 ± 3.28 
O2 cost (ml/kg/m): 
TD: 0.21 ± 0.05 
CP: 0.29 ± 0.07 
Higher O2 cost in CP group. P<0.05 
Dallmeijer and Brehm 2011 [58] 
Resting energy expenditure: 10 min (sitting 
while watching a video); 
5-min walk test: 5 min walking (circular 50-m 
indoor track) 
 Gross (net) ?̇?𝑶𝟐 walk (ml/kg/min): 
CP: 19.7 (13.7) ± 2.8 (2.2) 
TD: 16.1 (11.1) ± 3.6 (3.3) 
 EC (J/kg/m) 
CP: 5.47 ± 1.45 
TD: 3.96 ± 0.73 
(gross) O2 cost (ml/kg/m): 
CP: 0.27 ± 0.08 
TD: 0.20 ± 0.04 
Higher gross walking ?̇?𝑂2, O2 cost and EC in CP P<0.05 
Duffy et al., 1996 [59] 
2-3 min rest; 
3-4 min walking (10-m laboratory laps) 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 18.0 
Diplegic CP: 28.0 
Hemiplegic CP: 20.3 
O2 cost (ml/kg/m): 
TD: 0.24 
Diplegic CP: 0.64 
Hemiplegic CP: 0.42 
Higher ?̇?𝑂2 in diplegic CP compared to TD; higher O2 cost 
in both CP groups 
P<0.05 
Study Protocol Energy expenditure outcome (s) Main results SS 
Gupta and Raja 2019 [60] 
3 min rest (sitting); 
5 min outdoor walking 
(uneven surface - 100m figure-8 pathway) 
Net O2 cost (ml/kg/m): 
TD: 0.17 (0.13-0.19) 
CP: 0.59 (0.37-0.88) 
*Data as MEAN (C.I.) 
Higher net O2 cost in CP P<0.05 
Hoofwijk et al., 1995 [61] 
CWS: avg of 3x20m corridor walks 
Incremental test: 
Start: CWS + increments* (2 min) until FWS, 
then increments (2 min): 0.2-0.5 km/hr +2.4-5% 
gradient until exhaustion 
*not specified 
?̇?𝑶𝟐max (ml/kg/min): 
TD: 45.2 ± 8.4 
 CP: 32.7 ± 4.8 
?̇?𝑶𝟐max (L/min): 
TD: 2.29 ± 0.80 
 CP: 1.58 ± 0.68 
Lower ?̇?𝑂2max in CP P=0.001 
Johnston et al., 2004 [62] 
5 min rest (sitting); 
2 min walking warm up; 
5 min (at least) s-s walking (24-m oval track); 
3 min rest (sitting) 
O2 cost (ml/kg/m): 
TD: 0.23 ± 0.03 
CP: 0.79 ± 0.84 
GMFCS I: 0.28* 
GMFCS II: 0.44* 
GMFCS III: 0.63* 
GMFCS IV: 2.17* 
*as reported in graph 
Higher O2 cost in CP. Increasing O2 cost as a function of 




Kamp et al., 2014 [63] 
5 min rest (sitting); 
6 to 8 min walking; 
5 min rest (sitting) 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
GMFCS I: 15.51 (5.78)  
GMFCS II: 16.57 (6.64) 
GMFCS III: 18.92 (5.86) 
gross O2 cost (ml/kg/m): 
GMFCS I: 0.25 (0.89)  
GMFCS II: 0.31 (0.14) 
GMFCS III: 0.47 (0.27) 
EC (J/kg/m) 
GMFCS I: 5.20 (1.81) 
GMFCS II: 6.38 (2.68) 
GMFCS III: 9.80 (5.44) 
*Data as MEAN (IQ range) 
EC increases with severity: inverse relationship between 
EC and GMFCS level (R2=0.42) 
P<0.0001 (EC across 
GMFCS levels) 
Kerr et al., 2007 [64] 
5 min rest (sitting); 
5 min walking (20-m oval track); 
5 min recovery (sitting) 
Net O2 cost (ml/kg/m): 
GMFCS I: 0.14 
GMFCS II: 0.20 
GMFCS III: 0.33 
GMFCS IV: 0.54 
*reported in figure only 
Higher net O2 cost in GMFCS level II compared to III and 
III compared to IV 
P<0.001 (GMFCS II vs 
III and III vs IV) 
Kerr et al., 2008 [65] 
5-min rest (sitting); 
5-min walking (20-m oval track); 
5-min recovery (sitting) 
Net O2 cost (ml/kg/m): 
CP (total): 0.18 ± 0.10 
GMFCS I: 0.15 ± 0.04 
GMFCS II: 0.17 ± 0.07 
GMFCS III: 0.31 ± 0.12 
GMFCS IV: 0.36 ± 0.27 
Net O2 cost increases with severity (GMFCS level) 
P<0.001 (except for 
GMFCS I vs II and III vs 
IV) 
Kerr et al., 2011 [66] 
5-min rest (sitting); 
5-min walking (20-m oval track); 
5-min recovery (sitting) 
*re-assessment 2 years 7 months after baseline 
Net O2 cost (ml/kg/m): 
CP (baseline): 0.188 ± 0.105 
CP (2nd visit – 2 years, 8): 0.204 ± 0.110 
O2 cost decreased from 1st visit; 
weak relationship for age and O2 cost. 
P=0.04 (between visits) 
Study Protocol Energy expenditure outcome (s) Main results SS 
Maltais et al., 2004 [67] 
10 min rest; 
10-min treadmill walking (3 bouts) speed and 
slope set to yield the selected HR* (140-150 
b/min) in the heat (35 ± 1°C, 45-50% RH) 
*CP group (matched TD at same speed) 
?̇?𝑶𝟐 (L/min) - bout 1, 2, 3 
CP: 0.84 ± 0.08, 0.88 ± 0.11, 0.86 ± 0.12; 
TD: 0.57 ± 0.05, 0.62 ± 0.07, 0.62 ± 0.07 
Higher ?̇?𝑂2in CP group at each walking bout P<0.001 
Marconi et al., 2012 [68] 
3 min rest (standing); 
Incremental treadmill test (1km/h every 3/4 min – 
range: 1-6 km/h) 
Walking ?̇?𝑶𝟐 (ml/kg/min) – multiple subgroups at 
different walking speeds 
Net EC (J/kg/m) in figure only 
walking ?̇?𝑂2 interaction between “group” and “age”: 
Higher ?̇?𝑂2 and EC in diplegic CP for each age group; 
Higher ?̇?𝑂2 and EC in hemiplegic CP only for younger 
group. 
P<0.001 
Norman et al., 2004 [69] 
7 min rest; 
6 min walking (50-m oval path) 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 6.3 ± 1.9 
 CP: 19.7 ± 11.3 
OCI - net O2 cost (ml/kg/m): 
TD: 0.05 ± 0.02 
CP: 0.38 ± 0.24 
O2 cost* (ml/kg/m): 
TD: 0.09 ± 0.02 
CP: 0.55 ± 0.38 
*?̇?𝑶𝟐/distance walked 
Higher ?̇?𝑂2 at rest and during walking in CP; 
Higher O2 cost* and net O2 cost (OCI) in CP 
P<0.05 (?̇?𝑂2at rest, 
P<0.001 
Norman et al., 2006 [70] 
7 min [last 2 min] rest; 
6 min [4th and 5th] walking (50-m oval path) 
[considered for the analysis] 
Walking Energy Expenditure (kcal): 
TD: 5.6 ± 1.1 
 CP: 14.6 ± 5.1 
Net relative walking ?̇?𝑂2 higher in CP (values not reported) P<0.03 
Oeffinger et al., 2004 [71] N/A 
O2 cost (ml/kg/m): 
GMFCS I: 0.37 (0.11-1.4) 
GMFCS II: 0.47 (0.06-1.1) 
GMFCS III: 0.78 (0.28-2.5) 
*Data as MEAN (range) 
Higher O2 cost with increasing severity - positive 
relationship between GMFCS level and O2 cost (r= 0.61) 
P<0.05 (O2 cost across 
GMFCS), P<0.0001 
(relationship) 
Oeffinger et al., 2007 [72] N/A 
O2 cost (ml/kg/m): 
GMFCS I: 0.28 ± 0.1 
GMFCS II: 0.38 ± 0.2 
GMFCS III: 0.57 ± 0.3 
O2 cost increases with severity (GMFCS levels) 
P<0.05 (between each 
level) 
Piccinini et al., 2007 [73] 
2 min rest (sitting); 
7 laps (250m in total) of walking; 
2 min recovery (sitting) 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 15.6 ± 3.21 
CP: 13.97 ± 3.28 
O2 cost (ml/kg/m) 
TD: 0.21 ± 0.05 
CP: 0.29 ± 0.07 
Higher O2 cost in CP P<0.05 
Plasschaert et al., 2008 [74] 
5 min rest (sitting); 
8 min walking (34-m figure 8 track); 
5 min recovery (sitting) 
*2 tests in random order: 1) standard condition, 
2) addition of a 10% BW waist-belt 
(gross) Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 15.4 ± 2.3 
 CP: 20.7 ± 5.3 
gross O2 cost (ml/kg/m): 
TD: 0.223 ± 0.031 
CP: 0.393 ± 0.136 
(Values for standard condition only) 
Higher ?̇?𝑂2, gross O2 cost, in CP for both conditions P<0.001 
Rigby et al., 2017 [75] 
5 min rest; 
5-10 min treadmill walking (1.60934 km/h, 0% 
grade)* with 3-5 min s-s 
*speed originally reported in mph 
(gross) Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 9.80 ± 1.70 
CP: 16.70 ± 2.50 
EE (Kcal/min) 
TD: 2.20 ± 0.50 
CP: 2.80 ± 1.30 
Higher gross walking ?̇?𝑂2 in CP (Effect size= 0.71) P<0.001 
Study Protocol Energy expenditure outcome (s) Main results SS 
Rose et al., 1989 [76] 
starting speed: 21.5 m/min 
Steps (2 min): 29.5, 35.9, 51, 64.4, 77.8, 91.2, 
104.6, 118, 131.4 m/min 
End: running, unsteady gait or exhaustion 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 25.1 ± 5 
CP: 23.4 ± 7 
No between-group differences in ?̇?𝑂2 ,walking speed is 
lower in CP however 
NS 
Rose et al., 1990 [77] 
starting speed: 21.5 m/min 
Steps (2 min): 29.5, 35.9, 51, 64.4, 77.8, 91.2, 
104.6, 118, 131.4 m/min 
End: running, unsteady gait or exhaustion 
Economical EEI(O2) (ml/kg-m): 
TD: 0.17 ± 0.02 
CP: 0.48 ± 0.22 
Hemiplegic: 0.21 ± 0.01 
Diplegic: 0.56 ± 0.18 
Higher Economical EEI(O2) in CP; higher in diplegic 




Rose et al., 1993 [78] 
starting speed: 21.5 m/min 
Steps (2 min): 29.5, 35.9, 51, 64.4, 77.8, 91.2, 
104.6, 118, 131.4 m/min 
End: running, unsteady gait or exhaustion 
?̇?𝑶𝟐 (ml/min/kg): 
Slow speed (21.5 m/min) 
TD: 8.63 ± 1.27 
CP: 14.25 ± 3.67 
Faster speed (37.6 m/min) 
TD: 10.55 ± 1.24 
CP: 19.08 ± 7.20 
Economical speed 
TD: 15.4 ± 2.7 
CP: 22.8 ± 7.3 
At slow (21.5 m/min) and faster speed (37.6 m/min), 
higher ?̇?𝑂2 in CP, higher in diplegic compared to 
hemiplegic group. 
At economical speed, higher ?̇?𝑂2 for CP compared to TD 
and for diplegic compared to hemiplegic group. 
Slow speed: P=0.0001 
(CP-TD); P=0.008 
(Diplegic-Hemiplegic) 







Slaman et al., 2013 [79] 
3 min walking (12-m trajectory with smooth 
turns) 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
CP (all): 15.0 ± 4.4 
GMFCS I: 11.6 ± 3.2 
GMFCS II: 16.7 ± 3.9 
GMFCS III: 15.7 ± 4.9 
N/A N/A 
Steele et al., 2017 [80] 
3-10 min rest 
6-min walking test 
net nondimensional oxygen consumption (nn O2): 
TD: 0.10 ± 0.03 
CP: 0.18 ± 0.06 
At similar walking speed, average nn O2 for children with 
CP was 2.9 times that of speed-matched controls. Crouch 
severity was modestly related to nn O2 
N/A 
Thomas et al., 2009 [81] 
10-min rest; 
10 min walking (33m track); 
(3 tests within 1 month) 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
 CP(all): 19.77 ± 4.51 
GMFCS I: 18.66 ± 3.16 
GMFCS II: 20.81 ± 6.35 
GMFCS III: 20.32 ± 3.64 
gross O2 cost (ml/kg/min): 
 CP(all): 0.43 ± 0.24 
GMFCS I: 0.28 ± 0.05 
GMFCS II: 0.42 ± 0.13 
GMFCS III: 0.75 ± 0.23 
Significant day-to-day differences between all GMFCS 
levels for gross O2 cost; 
GMFCS level accounts for 58% of variance in gross O2 
cost 
P<0.01 
Thomas et al., 2011 [82] 
10-min rest; 
10 min walking (33m track); 
*re-assessment after 1 year (no intervention) 
Walking ?̇?𝑶𝟐 (ml/kg/min): 
BASELINE                       1yr 
TD: 16.1 ± 3.9;              13.7 ± 2.8 
GMFCS I: 17.0 ± 4;       16.9 ± 4.6 
GMFCS II: 19.5 ± 5;      19.4 ± 3.8 
GMFCS III: 20.3 ± 4;     16.9 ± 3.8 
Baseline: 
Higher ?̇?𝑂2 in GMFCS II compared to TD;  
1-year changes: reduction in resting and walking ?̇?𝑂2 
(TD), significant increase in walking ?̇?𝑂2 for GMFCS I and 
II compared to TD 
P<0.001 
P<0.01 (1-year change 
GMFCS I – TD) 
Trost et al., 2016 [83] 
3 walking trials (comfortable-, brisk- and fast-
speed); 
6 min rest (sitting) between tests 
(net) EE (METs): 
Comfortable speed 
GMFCS I: 2.8 (2.6-3.1)  
GMFCS II: 3.3 (2.9-3.7) 
GMFCS III: 3.5 (3.0-4.0) 
*Data as MEAN (95% CI) 
N/A N/A 
Study Protocol Energy expenditure outcome (s) Main results SS 
Unnithan et al., 1996 [84] 
1)Maximal test: 
speed increments (every 2 min) until FWS (no 
running), then gradient increments (every 2 min) 
2) Submaximal test (2 stages): 
4 min rest; 
4 min walking (3 km/h); 
8 min rest; 
4 min walking (90% of individual FWS) 
Gross (net) walking ?̇?𝑶𝟐 (ml/kg/min) 
3km/h: 
TD: 10.2 (5.8) ± 1.2 (0.84) 
CP: 16.6 (12.0) ± 6.5 (5.9) 
90% FWS: 
TD: 20.6 (16.2) ± 2.7 (1.9) 
CP: 20.5 (16.1) ± 4.9 (4.5) 
At low speed (3 km/h) higher ?̇?𝑂2 in CP. 
P<0.01 (net ?̇?𝑂2 at 3 
km/h) 
P<0.05 (gross walking 
?̇?𝑂2 at 3 km/h) 
Unnithan et al., 1999 [85] 
4 min rest (sitting); 
4 min treadmill walking (3 km/h, 0% grade) 
(net) Walking ?̇?𝑶𝟐 (ml/kg/min) 
TD: 10.2 ± 1.2 
CP: 16.6 ± 6.5 
Higher walking ?̇?𝑂2 in CP P<0.05 
Van de Walle et al., 2012 [86] 
5 min rest (sitting); 
3 min rest (standing); 
8 min walking (figure-eight track, 34 m) 
Net O2 cost (J/kg/m): 
TD adults: 1.8 [1.7 - 2.0] 
TD children: 2.7 [2.4 - 3.6] 
CP children: 4.2 [3.6 - 4.7] 
Median [IQ Range; IQ1 - IQ3] 
Net O2 cost increases progressively from TD adults, TD 
children and children with CP 
P=0.036 (CP-TD 
children), P<0.001 (CP-
TD adults, TD adults-
TD children) 
Van Den Hecke et al., 2007 [87] 
2 min rest (standing, s-s); 
2 min treadmill walking (s-s) 
Net walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 6.80 ± 2.00 
CP: 8.00 ± 2.60 
gross walking ?̇?𝑶𝟐 (ml/kg/min): 
TD: 13.00 ± 2.00 
CP: 14.60 ± 3.20 
Net energy cost - C (J/kg/m) 
TD: 2.85 ± 0.22 
CP: 3.68 ± 1.21 
 
Mean C value 1.3 time greater in CP. Gross and net ?̇?𝑂2 
1.2 times 
N/A 
CP, cerebral palsy; TD, typically developing; ?̇?𝑂2, oxygen consumption; GMFCS, Gross Motor Function Classification System (level); CWS, comfortable walking speed; FWS, fastest walking speed; N/A, not available; s-s, at steady-
state; SS, statistically significant; NS, not (statistically) significant; ECS, Energy Consumption; EC, Energy cost; NN, non-dimensional (normalized by leg length); ND NOC, net non-dimensional O2 cost (normalized by body mass 
and gravity); NOCh, net O2 cost with speed normalized to height. 
 
Table IV. Protocol details and testing modalities. CP vs TD: comparison between individuals with 
CP and TD; GMFCS: across GMFCS levels; Age: across different age groups or longitudinally. 
Overground: measurements were performed during overground walking; Treadmill: measurements 
were performed with subjects walking on a treadmill. 
Study 
Research design Testing type Outcome measure 
CP vs TD GMFCS Age Overground Treadmill V̇O2 O2 cost Other 
Aviram et al., 2011 [47] 
Balaban et al., 2012 [48] 
Balemans et al., 2017 [49] 
Bell and Davies 2010 [50] 
Bolster et al., 2017 [51] 
Bowen et al., 1998 [52] 
Boyd et al., 1999 [53] 
Brehm et al., 2007 [54] 
Campbell and Ball 1978 [55] n/a n/a 
Cardona Garcia et al., 2016 [56] 
Cimolin et al., 2007 [57] 
Dallmeijer and Brehm 2011 [58] 
Duffy et al., 1996 [59] 
Gupta and Raja 2019 [60] 
Hoofwijk et al., 1995 [61] 
Johnston et al., 2004 [62] 
Kamp et al., 2014 [63] 
Kerr et al., 2007 [64] 
Kerr et al., 2008 [65] 
Kerr et al., 2011 [66] 
Maltais et al., 2004 [67] 
Marconi et al., 2012 [68] 
Norman et al., 2004 [69] 
Norman et al., 2006 [70] 
Oeffinger et al., 2004 [71] 
Oeffinger et al., 2007 [72] n/a n/a 
Piccinini et al., 2007 [73] 
Plasschaert et al., 2008 [74] 
Rigby et al., 2017 [75] 
Rose et al., 1989 [76] 
Rose et al., 1990 [77] 
Rose et al., 1993 [78] 
Slaman et al., 2013 [79] 
Steele et al., 2017 [80] 
Thomas et al., 2009 [81] 
Thomas et al., 2011 [82] 
Trost et al., 2016 [83] 
Unnithan et al., 1996 [84] 
Unnithan et al., 1999 [85] 
Van de Walle et al., 2012 [86] 
Van Den Hecke et al., 2007 [87] 
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included in the review, ideally using a flow diagram. 
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16b Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. Page 9 
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17 Cite each included study and present its characteristics. Page 9-15 
Risk of bias in 
studies  
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19 For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its 
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20c Present results of all investigations of possible causes of heterogeneity among study results. NA 
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Reporting biases 21 Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. Page 16 
Certainty of 
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22 Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. NA 
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Search strategy in PubMed: 
((((((((((((cerebral palsy[MeSH Terms]) OR (cerebral palsy[Title/Abstract])) AND (fatigue[MeSH Terms])) 
OR (fatigue[Title/Abstract])) OR (energy metabolism[MeSH Terms])) OR (energy 
metabolism[Title/Abstract])) OR (metabolic cost[Title/Abstract])) OR (energy cost[Title/Abstract])) OR 
(VO2[Title/Abstract])) OR (endurance[Title/Abstract])) OR (energy expenditure[Title/Abstract])) OR 
(aerobic capacity[Title/Abstract])) OR (oxygen consumption[Title/Abstract]) 
 
Search strategy in CINAHL: 
#1 (MH “cerebral palsy”) 
#2 
(MH “fatigue”) OR (MH “energy metabolism”) OR (MH 
“metabolic cost”) OR (MH “energy cost”) OR (MH “VO2”) OR 
(MH “endurance”) OR (MH “aerobic capacity”) OR (MH 
“oxygen consumption”) 
#3 #1 AND #2 
 
 
Search strategy in Scopus: 
((cerebral palsy) AND (fatigue OR “energy metabolism” OR “metabolic cost” OR “energy cost” OR VO2 
OR endurance OR “energy expenditure” OR “aerobic capacity” OR “oxygen consumption”)) 
 
Search strategy in Web of Science: 
((cerebral palsy) AND (fatigue OR “energy metabolism” OR “metabolic cost” OR “energy cost” OR VO2 
OR endurance OR “energy expenditure” OR “aerobic capacity” OR “oxygen consumption”)) 
 
Search strategy in ScienceDirect: 
((cerebral palsy) AND (fatigue OR “energy metabolism” OR “metabolic cost” OR “energy cost” OR VO2 
OR endurance OR “energy expenditure” OR “aerobic capacity” OR “oxygen consumption”)) 
 
S3: Scores for methodological quality assessment for included studies (questions reported below). 
Study 
Research design - 




1 2 3 4 5 6 7 8 9 10 11 12 
Aviram et al., 2011 Case-control study - IV 5/12 (41.7) 0 0 0 1 1 0 0 1 0 1 0 1 
Balaban et al., 2012 Case-control study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Balemans et al., 2017 Case-control study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Bell and Davies, 2010 Case-control study - IV 8/12 (66.7) 1 1 1 1 1 0 0 1 0 1 0 1 
Bolster et al., 2017 Case-control study - IV 8/12 (66.7) 1 1 0 1 1 1 0 1 0 1 0 1 
Bowen et al., 1998 Case-control study - IV 7/12 (58.3) 0 0 1 1 1 1 0 1 0 1 0 1 
Boyd et al., 1999 Case-control study - IV 6/12 (50.0) 0 0 0 1 1 1 0 1 0 1 0 1 
Brehm et al., 2007 Case-control study - IV 5/12 (41.7) 0 0 0 1 1 0 0 1 0 1 0 1 
Campbell and Ball, 1978 Case-control study - IV 3/12 (25.0) 0 0 0 0 0 0 0 0 0 1 0 1 
Cardona Garcia et al., 2016 Case-control study - IV 8/12 (66.7) 1 1 1 1 1 0 0 1 0 1 0 1 
Cimolin et al., 2007 Case-control study - IV 7/12 (58.3) 1 0 1 1 1 0 0 1 0 1 0 1 
Dallmeijer and Brehm, 2011 Case-control study - IV 8/12 (66.7) 1 1 1 1 1 0 0 1 0 1 0 1 
Duffy et al., 1996 Case-control study - IV 5/12 (41.7) 0 1 0 1 1 0 0 0 0 1 0 1 
Gupta and Raja, 2019 Case-control study - IV 4/12 (33.3) 0 0 0 1 1 0 0 0 0 1 0 1 
Hoofwijk et al., 1995 Case-control study - IV 6/12 (50.0) 0 0 1 1 1 0 0 0 0 1 1 1 
Johnston et al., 2004 Case-control study - IV 4/12 (33.3) 0 0 0 1 1 0 0 0 0 1 0 1 
Kamp et al., 2014 Cohort study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Kerr et al., 2007 Cohort study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Kerr et al., 2008 Cohort study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Kerr et al., 2011 Cohort study - IV 8/12 (66.7) 1 1 0 1 1 0 0 1 0 1 1 1 
Maltais et al., 2004 Case-control study - IV 7/12 (58.3) 0 0 1 1 1 0 0 1 0 1 1 1 
Marconi et al., 2012 Case-control study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Norman et al., 2004 Case-control study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Norman et al., 2006 Case-control study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Oeffinger et al., 2004 Cohort study - IV 3/12 (25.0) 0 0 0 0 0 0 0 1 0 1 0 1 
Oeffinger et al., 2007 Cohort study - IV 6/12 (50.0) 1 1 0 0 0 0 0 1 1 1 0 1 
Piccinini et al., 2007 Case-control study - IV 7/12 (58.3) 1 0 1 1 1 0 0 1 0 1 0 1 
Plasschaert et al., 2008 Case-control study - IV 7/12 (58.3) 0 0 1 1 1 0 0 1 1 1 0 1 
Rigby et al., 2017 Case-control study - IV 6/12 (50.0) 1 1 0 1 0 0 0 1 0 1 0 1 
Rose et al., 1989 Case-control study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Rose et al., 1990 Case-control study - IV 6/12 (50.0) 1 1 0 1 1 0 0 0 0 1 0 1 
Rose et al., 1993 Case-control study - IV 6/12 (50.0) 1 1 0 1 1 0 0 0 0 1 0 1 
Slaman et al., 2013 Cohort study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Steele et al., 2017 Cohort study - IV 6/12 (50.0) 1 1 0 1 1 0 0 1 0 1 0 0 
Thomas et al., 2009 Cohort study - IV 6/12 (50.0) 1 0 0 1 1 0 0 1 0 1 0 1 
Thomas et al., 2011 Case-control study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Trost et al., 2016 Cohort study - IV 7/12 (58.3) 1 1 0 1 1 0 0 1 0 1 0 1 
Unnithan et al., 1996 Case-control study - IV 6/12 (50.0) 0 0 1 1 1 0 0 1 0 1 0 1 
Unnithan et al., 1999 Case-control study - IV 5/12 (41.7) 0 0 0 1 1 0 0 1 0 1 0 1 
Van de Walle et al., 2012 Case-control study - IV 7/12 (58.3) 1 1 1 1 1 0 0 1 0 0 0 1 
Van den Heke et al., 2007 Case-control study - IV 5/12 (41.7) 1 1 0 0 1 0 0 0 0 1 0 1 
 
  
Quality appraisal questions for methodological quality evaluation of articles (group research 
design studies). Adapted from the American Academy of Cerebral Palsy and Developmental 
Medicine (AACPDM) guidelines in the protocol by Morgan & J. McGinley (2014) Gait function 
and decline in adults with cerebral palsy: a systematic review, Disability and Rehabilitation, 
36:1, 1-9, DOI: 10.3109/09638288.2013.775359 
 
1. Were inclusion and exclusion criteria of the study population well described and followed? 
2. Is the sampling procedure (recruitment strategy) likely to minimize bias? 
3. The groups were similar at baseline regarding the most important prognostic indicators? 
4. Was the intervention well described and was there adherence to the intervention 
assignment? (For 2-group designs, was the control exposure also well described?) Both parts 
of the question need to be met to score ‘yes’. 
5. Were the measures used clearly described, valid and reliable for measuring the outcomes of 
interest? 
6. Were the measures sensitive to change for this population? Statement about the sensitivity 
of the measure to change. 
7. Was the outcome assessor(s) unaware of the intervention status of the participants (i.e., were 
the assessors masked)? 
8. Did the authors conduct and report appropriate statistical evaluation including measures of 
central tendency and variation? 
9. Did the authors report the power calculations for the sample size? 
10. Was a comparison made between groups with preservation of original group assignments? 
11. Were dropout/loss to follow-up reported for all subjects and less than 20%? For 2-group or 
more designs, was dropout balanced? 
12. The results of between-group statistical comparisons are reported for at least one key 
outcome? 
S4: Template of the data extraction form 
Data extraction form 
 
 
Paper title _______________________________________________________________________________________ 
 
Level of evidence 
 
Study design: ________________________________________ 
 
Level of evidence:  ______________________________________ 
 
Study meets inclusion criteria: _____________________________ 
 












Information about the study 
 




Age (range): ___ 
 



















I II III IV 
    
 













































































Aviram et al., 2011
Balaban et al., 2012
Balemans et al., 2017
Bell and Davies, 2010
Bolster et al., 2017
Bowen et al., 1998
Boyd et al., 1999
Brehm et al., 2007
Campbell and Ball, 1978
Cardona Garcia et al., 2016
Cimolin et al., 2007
Dallmeijer and Brehm, 2011
Duffy et al., 1996
Gupta and Raja, 2019
Hoofwijk et al., 1995
Johnston et al., 2004
Kamp et al., 2014
Kerr et al., 2007
Kerr et al., 2008
Kerr et al., 2011
Maltais et al., 2004
Marconi et al., 2012
Norman et al., 2004
Norman et al., 2006
Oeffinger et al., 2004
Oeffinger et al., 2007
Piccinini et al., 2007
Plasschaert et al., 2008
Rigby et al., 2017
Rose et al., 1989
Rose et al., 1990
Rose et al., 1993
Slaman et al., 2013
Steele et al., 2017
Thomas et al., 2009
Thomas et al., 2011
Trost et al., 2016
Unnithan et al., 1996
Unnithan et al., 1999
Van de Walle et al., 2012
Van den Heke et al., 2007
Low risk of bias Unclear risk of bias High risk of bias
S6: Box plot showing values of V̇O2 in TD and in CP across severity levels (GMFCS I to III). 
Triangles represent studies where values were converted or estimated by the authors of the review; 
dots indicate study originally measured data. Box plots depict the median and the 25th and 75th 
quartiles and the whiskers showing the minimum and maximum values. 
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S7a: Forest plot with pooled correlation coefficients (r) and C.I. for walking energy consumption 









Thomas et al. 2009 [81]
Thomas et al. 2011 [82]
Slaman et al. 2013 [79]
Kamp et al. 2014 [63]
Trost et al. 2016 [83]
Balemans et al. 2017 [49]
Bolster et al. 2017 [51]
















Heterogeneity: I2 = 98.07%
Test for overall effect: Z =  5.97 (p < 0.001)
Correlation (r)
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Johnston et al. 2004 [82]
Oeffinger et al. 2004 [71]
Kerr et al. 2007 [64]
Oeffinger et al. 2007 [72]
Kerr et al. 2008 [65]
Thomas et al. 2009 [81]
Thomas et al. 2011 [82]
Slaman et al. 2013 [79]
Kamp et al. 2014 [63]
Trost et al. 2016 [83]
Balemans et al. 2017 [49]
Bolster et al. 2017 [51]


























Heterogeneity: I2 = 94.19%
Test for overall effect: Z =  19.46 (p < 0.001)
Correlation (r)
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S8: Funnel plots and Egger’s test results for publication BIAS. 
 
 
Funnel plot 1: estimated publication bias for studies included in the V̇O2 analysis (TD-CP 
comparison). Egger's test not significant (p = 0.446). 
 
Funnel plot 2: estimated publication bias for studies included in the O2 cost analysis (TD-CP 










V̇O2- Funnel plot with pseudo 95% confidence limits




















O2cost - Funnel plot with pseudo 95% confidence limits










Egger's test (p= 0.628)
 
Funnel plot 3: estimated publication bias for studies included for the V̇O2 correlation analysis 
(across GMFCS levels). Egger's test was not performed (study n<10). 
 
Funnel plot 4: estimated publication bias for studies included for the O2 cost correlation analysis 
(across GMFCS levels). Egger's test not significant (p = 0.227). 
